Clinical trial NCT06501872: Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
Official title: Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Aortic Aneurysm
Keywords: Aortic Aneurysm
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
First posted: 2024-07-15
Enrollment: 80
Sex: ALL
Minimum age (years): 50
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effectiveness of using a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft as compared to previously published results of open surgical replacement of the aneurysmal aorta.

Detailed description: This study is a prospective, two-arm, traditional feasibility study of a physician modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft base device in adult patients meeting traditional size criteria for open surgical treatment of thoracoabdominal aortic aneurysms (TAAAs). Patients meriting surgical treatment of their aneurysm that also meet inclusion and exclusion criteria will be eligible for enrollment. Patients will be followed for 5 years post procedure.

Eligibility criteria: Main Arm Inclusion Criteria:

* Must be a man or woman 50 years of age or older by the date of informed consent
* Must have a thoracoabdominal aortic aneurysm of any Crawford classification (extent I-V) that extends no more proximal than the left subclavian artery.
* Must have an aneurysm size that meets standard indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta)
* Must be considered, in the judgement of the Investigator, to be a high- risk candidate for open surgical repair
* Must commit to comply with the five-year study assessment schedule of events
* Must have a non-aneurysm-related life expectancy, in the judgement of the Investigator, of greater than 2 years

Expanded Selection Inclusion Criteria:

* Must be a man or woman 50 years of age or older by the date of informed consent
* Must have a thoracic, thoracoabdominal, or abdominal aortic aneurysm that necessitates coverage of one or more visceral vessels (celiac, superior mesenteric, or renals) for establishment of proximal and/or distal seal. The aneurysm must not extend proximal to the left subclavian artery, or, in the setting of more proximal disease, that disease must have been previously treated.
* Must have an aneurysm size that meets standard size indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta); or, in the judgment of the Investigator, has aneurysm characteristics that portend a high risk of near-term rupture
* In the setting of an aortic dissection the following criteria must exist:

  * Access into the true lumen from the groin and at least one supra-aortic trunk vessel
  * A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent graft would be anticipated to seal off the dissection lumen
  * A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen, or surgically created
  * A true lumen size large enough to deploy the device and still gain access into the target branches
* Must be considered, in the judgement of the Investigator, to be a high-risk candidate for open surgical repair
* Patient must be able to provide informed consent
* Must commit to comply with the five-year study assessment schedule of events
* Must have a non-aneurysm-related life expectancy, in the judgement of the Investigator, of greater than 2 years

Main Arm Exclusion Criteria:

* Aneurysm due to acute or chronic dissection, intramural hematoma, penetrating aortic ulceration, pseudoaneurysm, mycotic aneurysm, or traumatic transection
* Ruptured or acutely symptomatic aortic aneurysm
* Known connective tissue disorder
* Imaging demonstrating any of the following:

  * Lack of 20 mm non-aneurysmal proximal seal zone (zone 3, or zone 2 with a carotid-subclavian bypass or transposition)
  * Lack of 15 mm non-aneurysmal distal seal zone(s) (aortic, common iliac, or external iliac)
  * Branch vessel target (renal, superior mesenteric, or celiac) \< 5 mm or \> 10 mm in average diameter
  * Untreated left subclavian artery stenosis or occlusion
  * Untreated unilateral or bilateral hypogastric artery occlusion
  * Signs that the inferior mesenteric artery is indispensable
  * Have branching, duplication, aneurysm, or untreatable stenosis of the celiac, superior mesenteric artery, or renal arteries that would preclude implantation of the investigational devices
* Known allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold
* History of anaphylaxis to contrast, with inability to prophylax appropriately.
* Have uncorrectable coagulopathy
* Have unstable angina
* Have a body habitus that would inhibit X-ray visualization of the aorta
* Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤30 days of the endovascular repair
* Known to be participating in any other clinical study which may affect performance of this - Ability to bear children
* Contraindication to oral antiplatelet therapy
* Prisoners or those on alternative sentencing
* Known systemic infection with potential for endovascular graft infection
* Anticipated need for MRI scanning within 3 months of insertion of investigational product
* Candidate for repair under the Instructions for Use of a commercially available, FDA-approved endovascular graft
* Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution.

Expanded Selection Exclusion Criteria:

* Known or suspected mycotic aneurysm
* Ruptured aneurysm with hemodynamic instability
* Known connective tissue disorder
* Imaging demonstrating any of the following:

  * Lack of 20 mm non-aneurysmal proximal seal zone (in either native aorta, elephant trunk graft, or aortic arch endograft)
  * Lack of 15 mm non-aneurysmal distal seal zone(s) (in either native aortoiliac vessels, prosthetic aortoiliac grafts, or aortoiliac endografts)
  * Branch vessel target (renal, superior mesenteric, or celiac) \> 10 mm in average diameter
* Known allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold
* History of anaphylaxis to contrast, with inability to prophylax appropriately.
* Have uncorrectable coagulopathy
* Have a body habitus that would inhibit X-ray visualization of the aorta
* Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair
* Known to be participating in any other clinical study which may affect performance of this device
* Ability to bear children
* Contraindication to oral antiplatelet therapy
* Prisoners or those on alternative sentencing
* Known systemic infection with potential for endovascular graft infection
* Anticipated need for MRI scanning within 3 months of insertion of investigational product
* Candidate for repair under the Instructions for Use of a commercially available, FDA- approved endovascular graft
* Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution
* Other conditions or comorbidities that, in the opinion of the Investigator, would exclude the patient

Primary outcomes:
measure: 30 day survival
timeFrame: 30 days
measure: Major Adverse Events (MAE) at 30 days following surgery
timeFrame: 30 days
measure: Treatment success at 12 months following surgery
timeFrame: 12 months
measure: Technical success at 12 months following surgery
timeFrame: 12 months
Secondary outcomes:
measure: Technical success on the day of surgery
timeFrame: Day of Surgery
measure: Aneurysm rupture
timeFrame: Day of Surgery
measure: Conversion to open repair
timeFrame: Day of Surgery
measure: Access site complication (Femoral or Iliac)
timeFrame: Day of Surgery
measure: Lower extremity ischemia
timeFrame: Day of Surgery
measure: Lower extremity compartment syndrome
timeFrame: Day of Surgery
measure: Stroke
timeFrame: Day of Surgery
measure: Paraplegia
timeFrame: Day of Surgery
measure: Paraparesis
timeFrame: Day of Surgery
measure: Death during surgery
timeFrame: Day of Surgery
measure: Survival rate
timeFrame: At 30, 183 days; 1, 2, 3, 4 and 5 years
measure: Major Adverse Events (MAEs)
timeFrame: At 30, 183 days; 1, 2, 3, 4 and 5 years
measure: Treatment success
timeFrame: At 30, 183 days; 2, 3, 4 and 5 years
measure: Aneurysm-Specific Quality of Life Survey
timeFrame: At Screening, 30, 183 days; 2, 3, 4 and 5 years
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchcock Medical Center
name: Bjoern D Suckow, MD
role: PRINCIPAL_INVESTIGATOR
References: